Dirk Haasner
Board of Directors
Pharmaceuticals
Lundbeck
Denmark
Biography
Dirk Haasner, Ph.D., MPM has been Senior Vice President of Global Regulatory Affairs & Manufacturing at Ovid Therapeutics Inc. since March 2016. Dr. Haasner serves as Head of Regulatory and Medical Affairs of USA at Lundbeck Pharmaceuticals Ltd. He served as Vice President of Global Regulatory Affairs at Ovid Therapeutics Inc. from December 2015 to March 2016. Dr. Haasner was Vice President of Regulatory and Medical Affairs and Vice President Regulatory Strategy and Policy at Lundbeck USA, Inc., from February 2002 to November 2015, with responsibility for all FDA interactions on several marketed orphan drugs and all Lundbeck development compounds. Dr. Haasner was co-founder of 4-Antibody AG and served as its Consultant. Since 2002, he has been Director of Pharma Marketing and Regulatory Affairs at Lundbeck Inc., where he was responsible for marketing Lundbeck's products in the US at a Lundbeck subsidiary in New York. He started an industry career in Pharma Project Management at Hoffmann-LaRoche, Basel, where he served as Vice Director and Global LifeCycle Leader for one of Roche's top selling products. From 1994 to 2002, Dr. Haasner was employed at F. Hoffmann-La Roche AG, where he held positions of increasing responsibility in global product development and global strategic marketing before being appointed Global Life-cycle Leader. Dr. Haasner is an expert in pharma marketing and regulatory affairs and was responsible for managing the interactions and communications with the Federal Drug Administration for Roche and he was also closely involved in the strategic development of the US market. Dr. Haasner obtained his PhD in Cell Biology and Immunology from the University of Basel for work on early B cell development done at the Basel Institute for Immunology and holds a postgraduate degree in Pharmaceutical Medicine from the EUCOR Universities Basel, Strasbourg and Freiburg. Dr. Haasner obtained a MSc in Molecular Biology at the University of Basel, Switzerland.
Research Interest
Pharmaceuticals
